Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

1.530 -0.080 (-4.97%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

February 08, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics to Present at Upcoming Investor Conferences

February 01, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

January 25, 2023

Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.

Via MarketBeat

Topics Workforce

8 Analysts Have This to Say About Century Therapeutics ↗

January 06, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 27, 2022 ↗

December 27, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

January 19, 2023

On Thursday, 29 stocks made new 52-week lows.

Via Benzinga

5 Health Care Stocks That Are Diving - And May Rally ↗

January 19, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

January 12, 2023

On Thursday, 13 stocks hit new 52-week lows.

Via Benzinga

Top 5 Health Care Stocks That May Surge ↗

January 10, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC ↗

January 06, 2023

Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest.

Via InvestorPlace

Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive ↗

January 06, 2023

Via Benzinga

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

January 05, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday ↗

December 20, 2022

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved ↗

November 22, 2022

This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...

Via Benzinga

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

November 11, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 10, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022

November 02, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗

October 31, 2022

Upgrades

Via Benzinga

Century Therapeutics to Present at the SITC 37th Annual Meeting

October 05, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors

October 03, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 25, 2022

Via Benzinga

FDA Announced Clearance To Century Therapeutics' Allogeneic Cell Therapy Candidate Study ↗

August 25, 2022

Century Therapeutics, Inc. (NASDAQ: IPSC) received ELiPSE-1 clinical study may proceed notification from the U.S. Food and Drug Administration (FDA) to assess CNTY-101 in patients with relapsed or...

Via Benzinga

U.S. Stock Futures Higher Following Friday's Rally ↗

June 27, 2022

Pre-open movers

Via Benzinga

92 Biggest Movers From Friday ↗

May 09, 2022

Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...

Via Benzinga

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch ↗

February 08, 2022

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 01, 2022

Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K...

Via Benzinga

60 Biggest Movers From Yesterday ↗

January 11, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.